Through partnerships India has access to two of those - AZ/Oxford's viral vector vaccine and Novavax's protein sub-unit vaccine with AZ/Oxford's vaccine ahead by a quarter," says the Bernstein report, which IANS has reviewed. "With their existing capabilities and capacities, SII is best positioned to commercialise one or both of the partnered vaccine candidates depending on approval timing, capacities and pricing." The way things look now, the report indicates that both vaccine candidates "will require two doses to be administered 21/28 days apart". Between SII, Bharat Biotech, Biological E, and some smaller players, India produces around 2.3 billion doses of various vaccines every year. The overall vaccine market in India is estimated at "$6 billion spread over FY 21-22", according to Bernstein.

Source: dna August 28, 2020 02:59 UTC